HDAC6 and Miyoshi myopathy: We and others have shown that HDAC6 inhibition synergistically enhances cytotoxicity of BTZ15, 16 or carfilzomib17 in MM and non-Hodgkin lymphoma cells41 by blocking protein degradation via both the aggresomal and protesomal pathways.